Streetbeat News

Price Targets

DE

Deutsche Bank analyst Nicole Deblase has maintained a Hold rating on Deere & Co. (DE) and lowered the price target from $425 to $401.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 8:54 pm

QSR

TD Cowen analyst Andrew Charles has reiterated an Outperform rating on Restaurant Brands Intl (NYSE:QSR) and maintained a $90 price target.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 8:54 pm

NVMI

Benchmark analyst Mark Miller maintains a Buy rating on Nova (NASDAQ:NVMI) and raises the price target from $150 to $187.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 8:54 pm

DBX

Goldman Sachs analyst Kash Rangan downgraded Dropbox (NASDAQ:DBX) from Neutral to Sell and reduced the price target from $26 to $24.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 8:54 pm

TTD

Benchmark analyst Mark Zgutowicz has maintained a Sell rating on Trade Desk (NASDAQ:TTD) but raised the price target from $32 to $42.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 8:54 pm

UBER

JMP Securities analyst Andrew Boone has maintained a Market Outperform rating on Uber Technologies (NYSE:UBER) and increased the price target from $76 to $85.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 8:03 pm

NRIX

Over the past three months, Nurix Therapeutics (NASDAQ:NRIX) has been evaluated by 4 analysts, showing a shift towards more bullish sentiments. The average 12-month price target for NRIX has been raised to $26.00, up from $23.50, with a high estimate of $31.00 and a low of $20.00. Analysts' actions include maintaining, raising, and lowering ratings and price targets, reflecting their response to Nurix's market dynamics and performance. Nurix Therapeutics, a biopharmaceutical company, focuses on developing treatments for cancer and immune disorders. Despite its impressive revenue growth rate of 71.13% as of August 31, 2023, it lags behind industry peers. The company's financial performance shows a high net margin of -200.26% and a ROE of -14.98%, indicating strong financial management but challenges in asset utilization and a conservative approach to debt with a debt-to-equity ratio of 0.03.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 8:01 pm

OPEN

Analyst ratings for Opendoor Technologies (NASDAQ:OPEN) show mixed sentiments, with recent updates varying from bullish to bearish. The average 12-month price target has increased to $3.95, up 16.86% from the previous $3.38. Despite this positive shift, Opendoor faces challenges, including a significant revenue decline of -70.84% as of September 30, 2023, and below-average net margin and ROA. However, its ROE outperforms industry benchmarks, and its conservative debt management is noted.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 8:00 pm

CROX

Nine analysts have recently updated their ratings on Crocs (NASDAQ:CROX), showing a mix of bullish and bearish sentiments. The majority are bullish, with 6 bullish, 2 somewhat bullish, and 1 indifferent. The average 12-month price target for CROX has been raised to $126.11, indicating a 10.87% increase from the previous target of $113.75. Analysts from firms like B. Riley Securities, Piper Sandler, and Raymond James have raised their price targets, reflecting optimism about Crocs's market performance. Crocs's financials show positive trends, with a revenue growth rate of 6.15% and a net margin of 16.93%, outperforming industry averages. However, the company's debt-to-equity ratio of 1.91 suggests financial risk.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 8:00 pm